Goldline Pharmaceutical share price
BSE: 544759Pharmaceuticals & BiotechnologySmall Cap
Last close ₹30.10up ₹0.12 (0.40%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹29.98.
Range of traded prices from listing on 19 May 2026 to 23 Oct 2026
₹28.13Low, 21 Oct 2026₹60.00High, 19 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29 Cr3,537th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 9 Jun 2026
- 7.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 9 Jun 2026
- 2.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 9 Jun 2026
- 28.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 9 Jun 2026
- 0.64
- Volume, BSEVolume. Shares traded on the last trading day.
- 6,000
Results
Standalone; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 9 Jun
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹17 Crup 24.57%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹2.76 Crup 103.70%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 16.0%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2025Filed 9 Jun | Mar 2026Filed 9 Jun |
|---|---|---|
| Revenue | 13.9 | 17.3 |
| Net profit | 1.4 | 2.8 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 9.8% | 16.0% |
Standalone. The 2 half years from Sep 2025, the first on record. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Wholesale trade of Pharmaceuticals, which carries all its revenue.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Goldline Pharmaceutical in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Jfl Life SciencesJFLLIFE | 34 | 5.0 | 0.7 | 4.6 | – | – | 15.9% | 15.9% | 0.00% |
 Sandu PharmaceuticalsSANDUPHQ | 33 | 18.5 | 0.8 | 8.8 | +4.2% | +10.3% | 4.1% | 5.3% | 2.94% |
 Medi CapsMEDICAPQ | 31 | – | 0.3 | – | −42.9% | – | −1.5% | −8.7% | 0.00% |
 Chandra Bhagat PharmaCBPL | 29 | 10.4 | 0.9 | – | +34.1% | +229.5% | 9.0% | – | 0.00% |
 Sunrest LifescienceSUNREST | 29 | 7.0 | – | – | – | – | 22.4% | – | 0.00% |
 Bacil PharmaBACPHAR | 29 | – | 1.1 | – | – | – | – | −0.7% | 0.00% |
 Gujarat Terce LaboratoriesGUJTERC | 27 | 12.7 | 2.7 | 7.6 | −7.2% | – | 25.8% | 25.8% | 0.00% |
 Lasa SupergenericsLASA | 25 | – | 0.5 | – | −95.2% | – | −24.8% | −24.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Sep 2026
Aug 2026
31 Aug · Meeting
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 30.10 | 30.10 | 30.10 | 30.10 | 30.10 | 6,000 |
| 21 Oct 2026 | 30.00 | 30.30 | 28.13 | 29.98 | 29.63 | 27,000 |
| 19 Oct 2026 | 32.01 | 32.01 | 32.00 | 32.00 | 32.01 | 6,000 |
| 16 Oct 2026 | 32.00 | 32.48 | 32.00 | 32.48 | 32.24 | 6,000 |
| 15 Oct 2026 | 32.99 | 32.99 | 31.56 | 31.56 | 32.27 | 6,000 |
| 14 Oct 2026 | 31.18 | 34.82 | 31.18 | 31.68 | 32.56 | 9,000 |
| 13 Oct 2026 | 32.50 | 32.50 | 32.50 | 32.50 | 32.50 | 6,000 |
| 12 Oct 2026 | 32.50 | 32.50 | 32.50 | 32.50 | 32.50 | 6,000 |
| 9 Oct 2026 | 32.50 | 32.50 | 32.50 | 32.50 | 32.50 | 3,000 |
| 7 Oct 2026 | 32.02 | 33.00 | 32.02 | 33.00 | 32.51 | 9,000 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- GOLDLINE PHARMACEUTICAL LIMITED
- BSE code
- 544759
- ISIN
- INE1CLW01015
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- May 2026
- Face value
- ₹10
In BSE SME IPO